

Claims

1. Use of SLN360 in the preparation of a medicament for the prophylaxis or treatment of a condition associated with elevated levels of Lp(a), wherein said SLN360 is to be administered in an individual dose of 100 mg to 600 mg.

5

2. Use according to claim 1, wherein an individual dose provides SLN360 in an amount of:

- 100-600 mg, 125-600 mg, 150-600 mg, 175-600 mg, 200-600 mg, 225-600 mg, 250-600 mg, 275-600 mg, 300-600 mg, 325-600 mg, 350-600 mg, 375-600 mg, 400-600 mg, 425-
 10 600 mg, 450-600 mg, 475-600 mg, 500-600 mg, 525-600 mg, 550-600 mg or 575-600 mg;
 100-575 mg, 125-575 mg, 150-575 mg, 175-575 mg, 200-575 mg, 225-575 mg, 250-575 mg, 275-575 mg, 300-575 mg, 325-575 mg, 350-575 mg, 375-575 mg, 400-575 mg, 425-
 575 mg, 450-575 mg, 475-575 mg, 500-575 mg, 525-575 mg or 550-575 mg;
 100-550 mg, 125-550 mg, 150-550 mg, 175-550 mg, 200-550 mg, 225-550 mg, 250-550
 15 mg, 275-550 mg, 300-550 mg, 325-550 mg, 350-550 mg, 375-550 mg, 400-550 mg, 425-
 550 mg, 450-550 mg, 475-550 mg, 500-550 mg or 525-550 mg;
 100-525 mg, 125-525 mg, 150-525 mg, 175-525 mg, 200-525 mg, 225-525 mg, 250-525
 mg, 275-525 mg, 300-525 mg, 325-525 mg, 350-525 mg, 375-525 mg, 400-525 mg, 425-
 525 mg, 450-525 mg, 475-525 mg or 500-525 mg;
 100-500 mg, 125-500 mg, 150-500 mg, 175-500 mg, 200-500 mg, 225-500 mg, 250-500
 20 mg, 275-500 mg, 300-500 mg, 325-500 mg, 350-500 mg, 375-500 mg, 400-500 mg, 425-
 500 mg, 450-500 mg or 475-500 mg;
 100-475 mg, 125-475 mg, 150-475 mg, 175-475 mg, 200-475 mg, 225-475 mg, 250-475
 mg, 275-475 mg, 300-475 mg, 325-475 mg, 350-475 mg, 375-475 mg, 400-475 mg, 425-
 25 475 mg or 450-475 mg;
 100-450 mg, 125-450 mg, 150-450 mg, 175-450 mg, 200-450 mg, 225-450 mg, 250-450
 mg, 275-450 mg, 300-450 mg, 325-450 mg, 350-450 mg, 375-450 mg, 400-450 mg or
 425-450 mg;
 100-425 mg, 125-425 mg, 150-425 mg, 175-425 mg, 200-425 mg, 225-425 mg, 250-425
 30 mg, 275-425 mg, 300-425 mg, 325-425 mg, 350-425 mg, 375-425 mg or 400-425 mg;
 100-400 mg, 125-400 mg, 150-400 mg, 175-400 mg, 200-400 mg, 225-400 mg, 250-400
 mg, 275-400 mg, 300-400 mg, 325-400 mg, 350-400 mg or 375-400 mg;
 100-375 mg, 125-375 mg, 150-375 mg, 175-375 mg, 200-375 mg, 225-375 mg, 250-375
 mg, 275-375 mg, 300-375 mg, 325-375 mg or 350-375 mg;
 35 100-350 mg, 125-350 mg, 150-350 mg, 175-350 mg, 200-350 mg, 225-350 mg, 250-350
 mg, 275-350 mg, 300-350 mg or 325-350 mg;

- 100-325 mg, 125-325 mg, 150-325 mg, 175-325 mg, 200-325 mg, 225-325 mg, 250-325 mg, 275-325 mg or 300-325 mg;
 100-300 mg, 125-300 mg, 150-300 mg, 175-300 mg, 200-300 mg, 225-300 mg, 250-300 mg or 275-300 mg;
- 5 100-275 mg, 125-275 mg, 150-275 mg, 175-275 mg, 200-275 mg, 225-275 mg or 250-275 mg;
 100-250 mg, 125-250 mg, 150-250 mg, 175-250 mg, 200-250 mg or 225-250 mg;
 100-225 mg, 125-225 mg, 150-225 mg, 175-225 mg or 200-225 mg;
 100-200 mg, 125-200 mg, 150-200 mg or 175-200 mg;
- 10 100-175 mg, 125-175 mg or 150-175 mg;
 100-150 mg or 125-150 mg; or
 100-125 mg.
3. Use according to claim 1 or claim 2 wherein an individual dose provides SLN360 in
 15 an amount of about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg or about 600 mg.
- 20 4. Use according to any one of claims 1 to 3 wherein an individual dose provides SLN360 in an amount of 300 mg.
5. Use according to any one of claims 1 to 3 wherein an individual dose provides SLN360 in an amount of 450 mg.
- 25 6. Use according to claim 1, wherein said SLN360 is to be administered in an individual dose of 300 mg to 600 mg.
7. Use according to claim 6, wherein an individual dose provides SLN360 in an
 30 amount of:
 300-600 mg, 325-600 mg, 350-600 mg, 375-600 mg, 400-600 mg, 425-600 mg, 450-600 mg, 475-600 mg, 500-600 mg, 525-600 mg, 550-600 mg or 575-600 mg;
 300-575 mg, 325-575 mg, 350-575 mg, 375-575 mg, 400-575 mg, 425-575 mg, 450-575 mg, 475-575 mg, 500-575 mg, 525-575 mg or 550-575 mg;
- 35 300-550 mg, 325-550 mg, 350-550 mg, 375-550 mg, 400-550 mg, 425-550 mg, 450-550 mg, 475-550 mg, 500-550 mg or 525-550 mg;

- 300-525 mg, 325-525 mg, 350-525 mg, 375-525 mg, 400-525 mg, 425-525 mg, 450-525 mg, 475-525 mg or 500-525 mg;
 300-500 mg, 325-500 mg, 350-500 mg, 375-500 mg, 400-500 mg, 425-500 mg, 450-500 mg or 475-500 mg;
- 5 300-475 mg, 325-475 mg, 350-475 mg, 375-475 mg, 400-475 mg, 425-475 mg or 450-475 mg;
 300-450 mg, 325-450 mg, 350-450 mg, 375-450 mg, 400-450 mg or 425-450 mg;
 300-425 mg, 325-425 mg, 350-425 mg, 375-425 mg or 400-425 mg;
 300-400 mg, 325-400 mg, 350-400 mg or 375-400 mg;
- 10 300-375 mg, 325-375 mg or 350-375 mg;
 300-350 mg or 325-350 mg; or
 300-325 mg.
8. Use according to claim 6 or claim 7 wherein an individual dose provides SLN360 in
 15 an amount of about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg,
 about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg,
 about 575 mg or about 600 mg.
9. Use according to any one of claims 6 to 8 wherein an individual dose provides
 20 SLN360 in an amount of 300 mg.
10. Use according to any one of claims 6 to 8 wherein an individual dose provides
 SLN360 in an amount of 450 mg.
- 25 11. Use according to any one of claims 1 to 10 wherein SLN360 is to be administered
 to a subject via a dosing regime comprising a plurality or course of doses.
12. Use according to claim 11 wherein administration is monthly, 2-monthly, 3-
 monthly, 4-monthly, 5-monthly, 6-monthly, 7-monthly, 8-monthly, 9-monthly, 10-monthly,
 30 11-monthly or 12-monthly.
13. Use according to claim 11 or claim 12 wherein administration is 4-monthly.
14. Use according to claim 11 or claim 12 wherein administration is 6-monthly.
- 35 15. Use according to claim 11 or claim 12 wherein an individual dose provides
 SLN360 in an amount of 300 mg and administration is 4-monthly.

16. Use according to claim 11 or claim 12 wherein an individual dose provides SLN360 in an amount of 300 mg and administration is 6-monthly.
- 5 17. Use according to claim 11 or claim 12 wherein an individual dose provides SLN360 in an amount of 450 mg and administration is 6-monthly.
18. Use according to claim 11 or claim 12 wherein the interval between consecutive doses is at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least
10 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.
19. Use according to claim 11 or claim 12 wherein the interval between consecutive doses is at least 4 months.
- 15 20. Use according to claim 11 or claim 12 wherein the interval between consecutive doses is at least 6 months.
21. Use according to claim 11 or claim 12 wherein an individual dose provides
20 SLN360 in an amount of 300 mg and the interval between consecutive doses is at least 4 months.
22. Use according to claim 11 or claim 12 wherein an individual dose provides SLN360 in an amount of 300 mg and the interval between consecutive doses is at least 6
25 months.
23. Use according to claim 11 or claim 12 wherein an individual dose provides SLN360 in an amount of 450 mg and the interval between consecutive doses is at least 6
30 months.
24. Use according to any one of the preceding claims wherein the SLN360 is to be administered by subcutaneous injection.
25. Use according to any one of the preceding claims wherein the condition
35 associated with elevated levels of Lp(a) is cardiovascular disease.

26. Use according to claim 25 wherein the condition associated with elevated levels of Lp(a) is atherosclerotic cardiovascular disease or atherosclerotic cerebrovascular disease

27. Use according to any one of the preceding claims wherein the condition associated with elevated levels of Lp(a)-containing particles is stroke (e.g., ischaemic stroke), atherosclerosis, thrombosis, coronary heart disease, aortic stenosis (e.g., calcific aortic stenosis), hyperlipidaemia, dyslipidaemia, coronary artery disease, peripheral arterial disease, abdominal aortic aneurysm, heart failure (e.g., heart failure secondary to ischaemic cardiomyopathy), or familial hypercholesterolaemia.

10

28. Use according to any one of claims 1 to 24 wherein the condition associated with elevated levels of Lp(a) is a cancer.

29. Use according to claim 28 wherein the cancer is prostate cancer.